Analysts Set Sotera Health Company (NASDAQ:SHC) Price Target at $17.80

Shares of Sotera Health Company (NASDAQ:SHC) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $17.80.

A number of brokerages have issued reports on SHC. Wall Street Zen upgraded shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Piper Sandler lifted their price objective on Sotera Health from $15.00 to $17.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their target price on Sotera Health from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. BMO Capital Markets assumed coverage on Sotera Health in a report on Thursday, November 13th. They issued an “outperform” rating and a $19.00 price target for the company. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sotera Health in a research note on Tuesday.

Insider Transactions at Sotera Health

In other Sotera Health news, Director Pincus & Co. Warburg sold 9,720,000 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $16.33, for a total transaction of $158,727,600.00. Following the sale, the director directly owned 34,102,952 shares of the company’s stock, valued at $556,901,206.16. This trade represents a 22.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gtcr Investment Xi Llc sold 12,000,000 shares of Sotera Health stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $15.65, for a total transaction of $187,800,000.00. Following the sale, the director owned 29,215,301 shares of the company’s stock, valued at approximately $457,219,460.65. This trade represents a 29.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 28,200,000 shares of company stock worth $452,346,000. 47.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Alpine Global Management LLC acquired a new stake in shares of Sotera Health during the third quarter worth $342,000. Voss Capital LP grew its position in shares of Sotera Health by 146.7% during the 3rd quarter. Voss Capital LP now owns 1,850,000 shares of the company’s stock valued at $29,100,000 after buying an additional 1,100,000 shares during the last quarter. Captrust Financial Advisors acquired a new stake in Sotera Health during the third quarter worth about $3,505,000. Woodline Partners LP bought a new position in Sotera Health in the third quarter worth about $8,348,000. Finally, Scientech Research LLC bought a new position in Sotera Health in the third quarter worth about $310,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Stock Up 1.1%

SHC opened at $16.75 on Friday. The company has a debt-to-equity ratio of 4.04, a quick ratio of 2.18 and a current ratio of 2.38. The company has a market cap of $4.76 billion, a price-to-earnings ratio of 88.16 and a beta of 1.81. Sotera Health has a one year low of $9.53 and a one year high of $17.78. The business’s fifty day moving average is $16.31 and its two-hundred day moving average is $14.35.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. Sotera Health had a return on equity of 43.69% and a net margin of 4.82%.The business had revenue of $311.31 million during the quarter, compared to analysts’ expectations of $303.63 million. Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. Analysts anticipate that Sotera Health will post 0.61 EPS for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.